Meals, Milk and Alcohol Changed CBD Exposure Without Producing the Same Pharmacokinetic Effect

Food and drinks changed measured CBD exposure by different amounts in a controlled human study. A higher plasma peak, greater total exposure and a later peak are separate findings; they should not be treated as synonyms.

One formulation and one administered dose

Healthy adults received a pharmaceutical CBD oral solution at a single 750-mg dose under different conditions. The randomized crossover design used a partially balanced schedule: every participant was not assigned every meal or drink condition. Plasma samples were collected for up to 96 hours to measure CBD and metabolites.

The size of the exposure change depended on the condition

Compared with fasting, a high-fat, high-calorie meal increased CBD total exposure, measured by AUC to infinity, approximately 3.8-fold and peak concentration approximately 5.2-fold. A low-fat meal and whole milk also increased exposure, but less markedly. Alcohol produced smaller increases in parent CBD exposure.

Those are relative pharmacokinetic comparisons for this formulation. They are not evidence that a particular meal increases clinical benefit by the same multiple. The study did not measure seizure control, pain relief or driving impairment as efficacy outcomes.

The metabolite result prevents an overly simple account

Peak timing and half-life of parent CBD did not show a clinically relevant change across the tested conditions. However, the metabolite 7-carboxy-CBD had a later peak with alcohol, and its behavior differed from that of parent CBD.

A statement that alcohol simply increased every cannabinoid measurement would therefore be inaccurate. Parent-drug and metabolite results must be named separately, along with the metric being compared.

Safety observations were limited

There were no severe or serious adverse events in this short study, but adverse events occurred, including more headaches and dizziness with the alcohol condition. That result does not endorse combining alcohol and CBD or establish long-term safety.

The sample was small, exposure varied substantially and the work was sponsored by the formulation’s manufacturer. When interpreting a concentration, the practical lesson is to obtain the formulation, dose, food and drink history and collection timing rather than infer dose or effects from a plasma number alone.

For the separate forensic question, see our discussion of cannabinoid concentrations and evidence of impairment.

Primary research

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia (2020). DOI: 10.1111/epi.16419.